GeNeuro SA (FRA:GEM)

Germany flag Germany · Delayed Price · Currency is EUR
0.0414
+0.0040 (10.70%)
At close: Dec 4, 2025
55.64%
Market Cap 1.31M
Revenue (ttm) n/a
Net Income (ttm) -14.76M
Shares Out n/a
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 49
Open 0.0414
Previous Close 0.0374
Day's Range 0.0414 - 0.0414
52-Week Range 0.0200 - 0.6300
Beta n/a
RSI 61.99
Earnings Date Feb 6, 2026

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 17
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GEM
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.